Research programme: NMDA receptor modulators - Allergan

Drug Profile

Research programme: NMDA receptor modulators - Allergan

Alternative Names: NMDA receptor modulators - Naurex; NRX-1050; NRX-1051; NRX-1059; NRX-105x; NRX-1060; NRX-2085; NRX-20xx

Latest Information Update: 22 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Naurex
  • Class Peptides; Small molecules
  • Mechanism of Action NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Brain injuries; Epilepsy; Neuropathic pain
  • No development reported Alzheimer's disease; Autistic disorder; Major depressive disorder; Schizophrenia

Most Recent Events

  • 10 Nov 2016 Preclinical development is ongoing for neuropathic pain in USA
  • 10 Nov 2016 Apintnyx receives three SBIR grants from divisions of the National Institutes of Health for development of novel compounds for Neuropathic pain and age-related cognitive decline
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top